ORAL ANTIDIABETICS AGENTS AVAILABLE IN INDIAN PHARMACEUTICAL MARKET: A PRICE VARIATION ANALYSIS
Objective: There are hundreds of brands in Indian markets for a single drug which is manufactured by various companies and thus leads to wide variation in prices for the same drug. Hence, we decide to evaluate the variation in price of different brands of the same drug available in Indian market.
Methods: An analysis was done for comparing price variations among various drugs prescribed in diabetes mellitus. Indian Drug Review (IDR) (2019 Volume XXV Issue 4) and Current Index of Medical Specialties (CIMS) (July 2019–October 2019) were referred to know the maximum and minimum price in INR of drugs in all available strength and dosage forms being manufactured by different companies in India and percentage price variation was calculated.
Results: Wide variation in the price of several brands of oral antidiabetics is found in Indian market. In single drug, highest price variation is found for glimepiride 1 mg tablet (1365.5%). In fixed-dose combinations (FDCs), highest price variation is found for glimepiride + metformin (2 mg + 500 mg) sustain release tablet (689.2%). Lowest price variation for FDCs was found for glimepiride + metformin (3 mg + 500 mg) tablet (4.8%). Furthermore, only few oral antidiabetic agents were included in the drug pricing control order 2013. Wide variation is seen in prices of brand and generic medicines.
Conclusion: All the stakeholders should collectively make efforts to reduce price variation among the various brands so as to make them affordable and aim to improve the health status of the community.
2. Rataboli PV, Garg A. Confusing brand names: Nightmare of medical profession. J Postgrad Med 2005;51:13-6.
3. Shankar PR, Subish P, Bhandari RB, Mishra P, Saha AC. Ambiguous pricing of topical dermatological products: A survey of brands from two South Asian countries. J Pak Assoc Dermatol 2006;16:134-40.
4. Ramanna MK, Ruckmani A, Janti SS, Eerike M, Prabu RL. Burden of therapy in patients suffering from diabetes mellitus and hypertension. Int J Pharm Pharm Sci 2017;9:210-5.
5. UK Essays. Oral Antidiabetic Drugs Available in Indian Market Economics Essay; 2018. Available from: https://www.ukessays.com/ essays/economics/oral-antidiabetic-drugs-available-in-indian-market-economics-essay.php?vref=1. [Last accessed on 2019 Nov 22].
6. Tripathi KD. Insulin, Oral Hypoglycaemic Drugs and Glucagon. In: Essential of Medical Pharmacology. 7th ed. New Delhi, India: Jaypee Brothers Medical Publishers Private Limited; 2013. p. 258-81.
7. Drug Price Control Order; 2013. Available from: http://www.nppaindia. nic.in/dpco2013.pdf. [Last accessed on 2019 Nov 22].
8. Tiwari A, Yadav P. Pharmaco-economic study of antidiabetic drugs. Int J Manag Appl Sci 2015;1:63-5.
9. Kumar R, Manu C, Singh DJ, Lakhani P, Tutu S, Dixit RK. The extent of price variation amongst branded antihypertensive drugs and its association with number of pharmaceutical companies. Int J Res Med Sci 2015;3:2800-6.
10. Chawan VS, Badwane SV, Gawand KV, Chhaya MU. Analysis of price variation amongst different formulations of anxiolytic drugs available in Indian market. Int J Res Med Sci 2016;4:2398-401.
11. Mamatha KR, Vishnu K. Price variation analysis of various brands of oral hypolipidemic drugs available in Indian pharmaceutical market. Int J Res Pharmacol Pharmacother 2017;6:381-8.
12. Patel BS, Chavda FM, Mundhava SG. Cost variation analysis of single nonsteroidal anti-inflammatory agents available in Indian market: An economic perspective. Int J Pharm Sci Res 2016;7:130-40.
13. Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: A literature review. P T 2012;37:45-55.
14. Atal S, Atal S, Deshmankar B, Nawaz SA. Cost analysis of commonly used drugs under price control in India: Assessing the effect of drug price control order on brand price variation. Int J Pharm Pharm Sci 2016;8:315-21.
15. Singal GL, Nanda A, Kotwani A. A comparative evaluation of price and quality of some branded versus branded-generic medicines of the same manufacturer in India. Indian J Pharmacol 2011;43:131-6.
16. Sood R. Generic, Drug Companies, Fleecing Patients. The Tribune. Chandigarh, India, Himachal Plus; 2010. Available from: http://www. tribuneindia.com/2010/20100210/himplus.htm#1. [Last accessed on 2019 Nov 20].
17. Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: A cross-sectional analysis of a survey in 11 developed countries. BMJ Open 2017;7:e014287.
18. Sari SP, Putri ID, Nursanti B. Cost-effectiveness analysis of ceftriaxone generic and patent in children with typhoid. Int J Appl Pharm 2018;10:76-80.
19. Parasiya SK, Balamuralidhara V, Kumar TM, Dave A, Gujarati R, Shukla A. Need for drug price control in India. Int J Drug Reg Aff 2018;1:12-8.
20. Kotwani A. Commentary: Will generic drug stores improve access to essential medicines for the poor in India? J Public Health Policy 2010;31:178-84.
21. Frazier LM, Brown JT, Divine GW, Fleming GR, Philips NM, Siegal WC, et al. Can physician education lower the cost of prescription drugs? A prospective, controlled trial. Ann Intern Med 1991;115:116-21.
22. Mehani R, Sharma P. Cost variation analysis of oral anti-diabetic drugs. Int J Basic Clin Pharmacol 2018;7:1709-14.
23. Sharma N, Mehta M, Dureja H, Chandra A. Pharmacoeconomic od antidiabetic drugs. Asian J Pharm 2018;12:1324-8.
24. Mamdani B. Drug deals. Indian J Med Ethics 2005;2:63-4.
25. Lavanya D, Dhivya K, Deekshitha P, Pravallika S, Kesini M. Attitude towards generic formulations usage: Narrowing the gap between pharmacist and physicians. Int J Pharm Pharm Sci 2019;11:117-20.
26. Mehar M, Shrivastav A, Jiwane D, Keer A. A cost analysis study of oral hypoglycemic drugs available in Indian market. World J Pharm Pharm Sci 2018;7:1237-45.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.